Articles
Atezolizumab plus bevacizumab versus sunitinib in patients
with previously untreated metastatic renal cell carcinoma
(IMmotion151): a multicentre, open-label, phase 3,
randomised controlled trial
Brian I Rini, Thomas Powles, Michael B Atkins, Bernard Escudier, David F McDermott, Cristina Suarez, Sergio Bracarda, Walter M Stadler, Frede Donskov,
Jae Lyun Lee, Robert Hawkins, Alain Ravaud, Boris Alekseev, Michael Staehler, Motohide Uemura, Ugo De Giorgi, Begoña Mellado, Camillo Porta,
Bohuslav Melichar, Howard Gurney, Jens Bedke, Toni K Choueiri, Francis Parnis, Tarik Khaznadar, Alpa Thobhani, Shi Li, Elisabeth Piault-Louis,
Gretchen Frantz, Mahrukh Huseni, Christina Schiff, Marjorie C Green, Robert J Motzer, on behalf of the IMmotion151 Study Group*
Summary
Background A phase 2 trial showed improved progression-free survival for atezolizumab plus bevacizumab versus Published Online
sunitinib in patients with metastatic renal cell carcinoma who express programmed death-ligand 1 (PD-L1). Here, we May 9, 2019
report results of IMmotion151, a phase 3 trial comparing atezolizumab plus bevacizumab versus sunitinib in first- http://dx.doi.org/10.1016/
S0140-6736(19)30723-8
line metastatic renal cell carcinoma.
See Online/Comment
http://dx.doi.org/10.1016/
Methods In this multicentre, open-label, phase 3, randomised controlled trial, patients with a component of clear cell S0140-6736(19)30949-3
or sarcomatoid histology and who were previously untreated, were recruited from 152 academic medical centres and *Investigators listed in the
community oncology practices in 21 countries, mainly in Europe, North America, and the Asia-Pacific region, and appendix
were randomly assigned 1:1 to either atezolizumab 1200 mg plus bevacizumab 15 mg/kg intravenously once every Taussig Cancer Institute,
3 weeks or sunitinib 50 mg orally once daily for 4 weeks on, 2 weeks off. A permuted-block randomisation (block size Cleveland Clinic, Cleveland, OH,
USA (B I Rini MD); Barts Cancer
of 4) was applied to obtain a balanced assignment to each treatment group with respect to the stratification factors.
Institute and the Royal Free
Study investigators and participants were not masked to treatment allocation. Patients, investigators, independent Hospital, Queen Mary
radiology committee members, and the sponsor were masked to PD-L1 expression status. Co-primary endpoints were University of London, London,
investigator-assessed progression-free survival in the PD-L1 positive population and overall survival in the intention- UK (T Powles MD); Georgetown
Lombardi Comprehensive
to-treat (ITT) population. This trial is registered with ClinicalTrials.gov, number NCT02420821.
Cancer Center, Washington, DC,
USA (M B Atkins MD); Gustave
Findings Of 915 patients enrolled between May 20, 2015, and Oct 12, 2016, 454 were randomly assigned to the Roussy, Villejuif, France
atezolizumab plus bevacizumab group and 461 to the sunitinib group. 362 (40%) of 915 patients had PD-L1 positive (B Escudier MD); Beth Israel
Deaconess Medical Center,
disease. Median follow-up was 15 months at the primary progression-free survival analysis and 24 months at the
Boston, MA, USA
overall survival interim analysis. In the PD-L1 positive population, the median progression-free survival was (D F McDermott MD); Vall
11·2 months in the atezolizumab plus bevacizumab group versus 7·7 months in the sunitinib group (hazard ratio d’Hebron Institute of
[HR] 0·74 [95% CI 0·57–0·96]; p=0·0217). In the ITT population, median overall survival had an HR of 0·93 Oncology, Vall d´Hebron
University Hospital,
(0·76–1·14) and the results did not cross the significance boundary at the interim analysis. 182 (40%) of 451 patients
Universitat Autònoma de
in the atezolizumab plus bevacizumab group and 240 (54%) of 446 patients in the sunitinib group had treatment- Barcelona, Barcelona, Spain
related grade 3–4 adverse events: 24 (5%) in the atezolizumab plus bevacizumab group and 37 (8%) in the sunitinib (C Suarez MD); Azienda
group had treatment-related all-grade adverse events, which led to treatment-regimen discontinuation. Ospedaliera S Maria, Terni, Italy
(S Bracarda MD); The University
of Chicago Medicine, Chicago,
Interpretation Atezolizumab plus bevacizumab prolonged progression-free survival versus sunitinib in patients with IL, USA (W M Stadler MD);
metastatic renal cell carcinoma and showed a favourable safety profile. Longer-term follow-up is necessary to establish Department of Oncology,
whether a survival benefit will emerge. These study results support atezolizumab plus bevacizumab as a first-line Aarhus University Hospital,
Aarhus, Denmark
treatment option for selected patients with advanced renal cell carcinoma.
(F Donskov DMSc); Department
of Oncology, Asan Medical
Funding F Hoffmann–La Roche Ltd and Genentech Inc. Center, University of Ulsan
College of Medicine, Seoul,
South Korea (J L Lee MD);
Copyright © 2019 Elsevier Ltd. All rights reserved.
The Christie NHS Foundation
Trust, Manchester, UK
Introduction almost all patients acquire resistance over time.4 (R Hawkins PhD); CHU Hôpitaux
de Bordeaux–Hôpital
In patients with locally advanced or metastatic renal Efficacy is particularly low in some patient subgroups,
Saint-André, Bordeaux, France
cell carcinoma, tyrosine kinase inhibitors targeting including cases with a sarcomatoid differentiation5
(A Ravaud MD); P Herzen
vascular endothelial growth factor (VEGF), such as and disease expressing programmed death-ligand 1 Oncology Research Institute,
sunitinib, have been the first-line standard of care for (PD-L1).6–8 Additionally, the use of these drugs can be Moscow, Russia
(B Alekseev MD); Klinikum der
the past decade.1–3 However, many patients have disease limited by adverse events, such as diarrhoea, fatigue,
Universität München, Campus
that is inherently resistant to these approaches, and palmar-plantar erythrodysaesthesia, and mucositis,
www.thelancet.com Published online May 9, 2019 http://dx.doi.org/10.1016/S0140-6736(19)30723-8 1
Articles
Großhadern, München,
Germany (M Staehler MD); Research in context
Department of Urology, Osaka
Evidence before this study Added value of this study
University Graduate School of
Medicine, Osaka, Japan We searched PubMed and international congress presentations The IMmotion151 trial met its coprimary endpoint, showing
(M Uemura MD); Istituto pertaining to studies in metastatic renal cell carcinoma between improved investigator-assessed progression-free survival with
Scientifico Romagnolo per lo
May 1, 2010, and May 1, 2015, for articles published in English atezolizumab plus bevacizumab versus sunitinib in patients
Studio e la Cura dei Tumori,
with MeSH search terms “metastatic” AND “kidney cancer”, with metastatic renal cell carcinoma whose disease expressed
IRCCS, Meldola, Italy
(U De Giorgi MD); Hospital “renal cell carcinoma”, “programmed cell death 1”, “PD-1”, PD-L1. Clinical efficacy is further supported by higher objective
Clínic of Barcelona, Institut “programmed cell death ligand 1”, and “PD-L1”. We identified an response rates, especially complete response rates,
d’Investigacions Biomèdiques
unmet clinical need for effective and tolerable approaches to the with atezolizumab plus bevacizumab versus sunitinib
August Pi i Sunyer, Barcelona,
Spain (B Mellado MD); IRCCS treatment of patients with metastatic renal cell carcinoma. treatment. Overall survival did not cross the significance
San Matteo University Hospital Approved therapies in the first-line metastatic setting included boundary, and longer-term follow-up is necessary to establish
Foundation, Pavia, Italy tyrosine kinase inhibitors, such as sunitinib and pazopanib, whether a survival benefit will emerge. Patients given
(C Porta PhD); Lékařská Fakulta
and the combination of the vascular endothelial growth factor atezolizumab plus bevacizumab had improved progression-free
Univerzita Palackého a Fakultní
Nemocnice Olomouc, Olomouc, (VEGF) inhibitor bevacizumab with interferon alfa-2a; however, survival regardless of the clinical risk group examined, including
Czech Republic (B Melichar MD); these therapies are associated with considerable morbidity due patients with previous nephrectomy, sarcomatoid histology,
Department of Clinical to adverse events and do not result in a sustained, durable and established prognostic risk scores, including patients with
Medicine, Macquarie
clinical benefit. Additionally, elevated programmed favourable prognostic risk. The combination of atezolizumab
University, Sydney, NSW,
Australia (H Gurney MBBS); death-ligand 1 (PD-L1) expression on tumour-infiltrating plus bevacizumab was shown to have a tolerable safety profile
Department of Urology, immune cells is often associated with a worse prognosis in renal consistent with previous studies and was associated with fewer
University of Tübingen, cell carcinoma. Checkpoint inhibitors, such as atezolizumab, high-grade treatment-related adverse events and a lower
Tübingen, Germany
nivolumab, and pembrolizumab, target the PD-L1 or regimen discontinuation rate versus sunitinib, and low
(J Bedke MD); Dana-Farber
Cancer Institute, Boston, MA, programmed cell death protein 1 (PD-1) pathway and represent corticosteroid use. Additionally, patients reported a delay in
USA (T K Choueiri MD); Ashford an attractive strategy to reinvigorate tumour-specific T-cell symptom interference with daily living when given
Cancer Centre Research, immunity. Despite numerous advancements, metastatic renal atezolizumab plus bevacizumab versus sunitinib. Results
Kurralta Park, SA, Australia
cell carcinoma remains a largely incurable disease because a support the clinical activity of checkpoint inhibitor-based
(F Parnis MBBS); F Hoffmann–La
Roche, Basel, Switzerland substantial majority of patients develop resistance to standard combinations in first-line metastatic renal cell carcinoma.
(T Khaznadar MSc); Roche therapies, including VEGF-directed drugs or immunotherapy.
Products Ltd, Welwyn Garden Therefore, an ongoing need exists for more-efficacious and Implications of all the available evidence
City, UK (A Thobhani MSc);
better-tolerated treatments. Collectively, the role of VEGF in the Given that both the VEGF and PD-L1 pathways are important
Genentech, Inc, South
San Francisco, CA, USA immune response and its crucial role in renal cell carcinoma in renal cell carcinoma pathogenesis, concomitant inhibition
(S Li PhD, E Piault-Louis PharmD, pathogenesis provide a compelling rationale to test whether of VEGF signalling might enhance the efficacy of
G Frantz PhD, M Huseni MS, dual inhibition of the PD-L1–PD-1 and VEGF pathways will result immunotherapy in the front-line treatment of patients with
C Schiff MD, M C Green MD); and
in improved clinical benefit for patients with metastatic renal metastatic renal cell carcinoma. Results from this study and
Memorial Sloan Kettering
Cancer Center, New York, NY, cell carcinoma. others support this hypothesis.
USA (R J Motzer MD)
Correspondence to:
Dr Brian Rini, Taussig Cancer which impair patients’ quality of life,9,10 underscoring a reversal of VEGF-mediated immunosuppression mech-
Institute, Cleveland Clinic, need for new therapeutic targets and drug combinations anisms by the addition of bevacizumab.20
Cleveland, OH 44195, USA
for patients with meta static renal cell carcinoma. Objective responses for atezolizumab plus bevacizumab
rinib2@ccf.org
Treatment with check point inhibitors, including the were first observed in a phase 1b study18 in metastatic renal
See Online for appendix
anti-PD-L1 antibody atezolizumab, has resulted in cell carcinoma. Subsequently, a phase 2 study11 assessed
durable responses and improvements in overall survival atezolizumab alone and in combination with bevacizumab
in pre-treated patients with metastatic renal cell versus sunitinib. Atezolizumab plus bevacizumab
carcinoma.7,11,12 improved progression-free survival and the proportion of
Bevacizumab binds to VEGF and is approved in patients who achieved an objective response versus
combination with interferon alfa for metastatic renal cell sunitinib in the subgroup of patients with disease
carcinoma.13 In addition to its antiangiogenic effects,14 expressing PD-L1. Atezolizumab also showed antitumour
VEGF blockade by bevacizumab modulates the immune activity when administered as a single drug, supporting
environment, including enhancing T-cell priming and complementary activity of bevacizumab plus atezolizumab
activation via promotion of dendritic cell maturation,15,16 in patients with metastatic renal cell carcinoma.
increasing T-cell tumour infiltration by normalising We report the primary analysis of the efficacy and safety
tumour vasculature,17,18 and establishing an immune- of atezolizumab plus bevacizumab versus sunitinib in the
permissive tumour microenvironment by decreasing IMmotion151 study, the first randomised, phase 3 trial
myeloid-derived suppressor-cell and regulatory T-cell combining an anti-PD-L1–PD-1 antibody with an anti-
populations.18,19 Therefore, T-cell-mediated cancer-cell VEGF drug as treatment for patients with metastatic renal
killing by atezolizumab could be enhanced through cell carcinoma.
2 www.thelancet.com Published online May 9, 2019 http://dx.doi.org/10.1016/S0140-6736(19)30723-8
Articles
1228 patients screened
313 did not meet eligibility criteria
915 enrolled
454 randomly assigned to 461 randomly assigned to sunitinib
atezolizumab plus bevacizumab
3 did not receive any treatment 15 did not receive any treatment
1 died 10 withdrew
1 physician decision 2 physician decision
1 non-adherence 1 died
2 other
451 treated and analysed for safety 446 treated and analysed for safety
267 discontinued atezolizumab 308 discontinued treatment
275 discontinued bevacizumab
265 discontinued both
131 ongoing in 134 discontinued 184 ongoing on study 153 ongoing in 155 discontinued 138 ongoing on study
survival follow-up study treatment with survival follow-up study treatment
115 died atezolizumab 128 died
1 physician 176 ongoing on study 3 physician
decision treatment with decision
17 withdrew bevacizumab 21 withdrew
1 other (lost to 3 other (lost to
follow-up, follow-up,
non- non-
adherence) adherence)
Figure 1: Trial profile
Methods inclusion and exclusion criteria is available in the
Study design and participants appendix. All patients gave written informed consent.
We did a multicentre, open-label, phase 3, randomised The study protocol (appendix) was approved by the
controlled trial at 152 academic medical centres and institutional review board or independent ethics com-
community oncology practices in 21 countries, mainly mittee for each study site and was done in full accordance
in Europe, North America, and the Asia-Pacific region with the Guideline for Good Clinical Practice and the
(Australia, Bosnia and Herzegovina, Brazil, Canada, Declaration of Helsinki.
Czech Republic, Denmark, France, Germany, Italy,
Japan, South Korea, Mexico, Poland, Russia, Singapore, Randomisation and masking
Spain, Taiwan, Thailand, Turkey, UK, and USA; Patients were randomly assigned (1:1) via an interactive
appendix). Eligible patients were aged 18 years or older voice and web response system to receive atezolizumab
with unresectable locally advanced or metastatic renal plus bevacizumab or sunitinib. A permuted-block ran-
cell carcinoma with any component of clear cell or domisation (block size of 4) was applied to obtain a
sarcomatoid histology (per local pathology report), balanced assignment to each treatment group with respect
measurable disease according to Response Evaluation to the stratification factors, including PD-L1 expression
Criteria in Solid Tumours version 1.1 (RECIST 1.1), (<1% vs ≥1% of tumour-infiltrating immune cells
Karnofsky perfor mance status 70% or higher, adequate expressing PD-L1 as assessed by immuno histochemistry
haem atological and end-organ function, and tumour [VENTANA PD-L1 SP142 assay; Ventana Medical Systems,
tissue available for PD-L1 testing. Patients were excluded Tucson, AZ]), presence of liver metastasis (yes vs no), and
if they had received previous systemic treatment or if Memorial Sloan Kettering Cancer Center (MSKCC)
they had untreated brain metastases. A full list of prognostic risk score (0, 1–2, ≥3).21 The trial centres
www.thelancet.com Published online May 9, 2019 http://dx.doi.org/10.1016/S0140-6736(19)30723-8 3
Articles
infusions once every 3 weeks. Patients randomly assigned
PD-L1 positive (n=362) Intention to treat (n=915)
to the sunitinib group received sunitinib 50 mg once
Atezolizumab Sunitinib Atezolizumab Sunitinib daily orally for 4 weeks, followed by 2 weeks of rest.
plus bevacizumab (n=184) plus bevacizumab (n=461)
Atezolizumab, bevacizumab, and sunitinib were provided
(n=178) (n=454)
by the sponsor, except when sunitinib was procured as
Age, years 62 (55–67) 59 (53–65) 62 (56–69) 60 (54–66)
local commercial product in some countries (Japan, USA,
Sex
and Canada). Patients could continue atezolizumab plus
Male 120 (67%) 146 (79%) 317 (70%) 352 (76%)
bevacizumab or sunitinib beyond disease progression
Female 58 (33%) 38 (21%) 137 (30%) 109 (24%)
according to RECIST 1.1 and the investigator’s discretion
Geographical region if evidence of clinical benefit was observed. No prespecified
USA and Canada 46 (26%) 35 (19%) 97 (21%) 84 (18%) crossover was planned per protocol.
Western Europe and 70 (39%) 89 (48%) 195 (43%) 219 (48%) Patients had tumour assessments at baseline, week 12,
Australia
and then every 6 weeks up to week 78, followed by every
Asia 31 (17%) 25 (14%) 80 (18%) 73 (16%)
12 weeks thereafter, until disease progression according to
Eastern Europe 30 (17%) 29 (16%) 69 (15%) 70 (15%)
RECIST 1.1 or loss of clinical benefit. Survival follow-up
Central and South America 1 (1%) 6 (3%) 13 (3%) 15 (3%)
occurred every 3 months after treatment disc ontinuation.
Karnofsky performance status
National Cancer Institute Common Terminology Criteria
<80 9 (5%) 9 (5%) 40 (9%) 35 (8%)
for Adverse Events version 4.0 was used to assess frequency
80–90 94 (53%) 96 (52%) 242 (53%) 228 (49%)
and severity of adverse events.
100 75 (42%) 79 (43%) 172 (38%) 198 (43%) Symptom severity for 17 symptoms and symptom
MSKCC risk score interference with activities of daily living were captured
Favourable (0) 31 (17%) 31 (17%) 89 (20%) 90 (20%) by the MD Anderson Symptom Inventory (MDASI),
Intermediate (1 or 2) 128 (72%) 133 (72%) 311 (69%) 318 (69%) which patients completed before initiating treatment
Poor (≥3) 19 (11%) 20 (11%) 54 (12%) 53 (12%) (baseline), on day 1 and day 22 of each cycle, at end of
Most common metastatic sites treatment, and during survival follow-up. The range for
Bone 32 (18%) 41 (22%) 90 (20%) 90 (20%) each symptom severity and symptom interference score
Liver 30 (17%) 33 (18%) 78 (17%) 82 (18%) is 0–10, with higher scores indicating greater symptom
Lung 135 (76%) 136 (74%) 339 (75%) 325 (71%) severity and interference. Time to clinically relevant
Lymph node 89 (50%) 90 (49%) 211 (47%) 218 (47%) deterioration of day-to-day functioning was based on a
Previous nephrectomy 150 (84%) 152 (83%) 334 (74%) 330 (72%) 2-point or higher increase above baseline on the six-item
Disease PD-L1 expression on tumour-infiltrating immune cells MDASI interference subscale, where patients rated how
≥1% 178 (100%) 184 (100%) 178 (39%) 184 (40%) much their symptoms interfered with work, general
<1% 0 0 276 (61%) 277 (60%) activity, walking, enjoyment of life, mood, and relations
Predominant histology with other people.22
Clear cell carcinoma 163 (92%) 160 (87%) 420 (93%) 425 (92%)
Sarcomatoid 12 (7%) 17 (9%) 22 (5%) 22 (5%) Outcomes
Other* 3 (1%) 7 (4%) 12 (2%) 14 (3%) Co-primary endpoints were progression-free survival
Sarcomatoid differentiation† 36 (20%) 50 (27%) 68 (15%) 74 (16%) (RECIST 1.1) by investigator assessment in patients
with PD-L1 positive disease (defined as ≥1% expression
Data are n (%) or median (IQR). MSKCC=Memorial Sloan Kettering Cancer Center. PD-L1=programmed death-ligand 1.
*Includes papillary, chromophobe, and oncocytoma. †Any component of sarcomatoid differentiation regardless of on tumour-infiltrating immune cells) and overall
predominant histology. survival in the intention-to-treat (ITT) population. Key
secondary objectives included overall survival in the
Table 1: Baseline characteristics
PD-L1 positive population, progression-free survival in
the ITT population, the proportion of patients who
enrolled the patients. The study was open label, and achieved an objective response, duration of response,
investigators and participants were not masked to patient-reported outcomes, and safety. Radiographic
treatment allocation. Patients, investigators, independent endpoints were also assessed by an IRC. A complete list
radiology committee (IRC) members, and the sponsor of outcomes is reported in the protocol (see appendix).
were masked to PD-L1 expression status. The sponsor was
not permitted to carry out any population-level summaries Statistical analysis
of outcome data by treatment group until the time of We randomly assigned 915 patients, including 362 patients
primary analysis. with a PD-L1 immunohistochemistry tumour-infiltrating
immune cell score of 1% or higher. The type 1 error () for
Procedures the entire study is 0·05 (two-sided), which we split
Patients randomly assigned to the atezolizumab plus between the co-primary endpoints of progression-free
bevacizumab group received atezolizumab 1200 mg survival in patients with PD-L1 positive disease (=0·04)
intravenously then bevacizumab 15 mg/kg intravenous and overall survival in the ITT population (=0·01) to
4 www.thelancet.com Published online May 9, 2019 http://dx.doi.org/10.1016/S0140-6736(19)30723-8
Articles
A B
100
90
80
70
60
50
40
30
20
10
0
0 3 6 9 12 15 18 21 24 27 0 3 6 9 12 15 18 21 24 27
Number at risk
(number censored)
Atezolizumab plus 178 (0) 137 (5) 117 (7) 94 (9) 79 (11) 55 (26) 22 (49) 5 (64) ·· ·· 454 (0) 355 (10)294 (17)236 (24)196 (32)126 (74)57 (126)15 (159) 1 (170) ··
bevacizumab group
Sunitinib group 184 (0) 135 (5) 110 (6) 83 (7) 64 (10) 44 (17) 15 (37) 7 (44) 1 (49) ·· 461 (0) 346 (15)281 (19)211 (24)166 (33)105 (70)42 (116)14 (140) 1 (151) ··
Figure 2: Progression-free survival (investigator-assessed) and overall survival
Progression-free survival in the PD-L1 positive (A) and intention-to-treat populations (B). Progression was defined according to Response Evaluation Criteria in Solid Tumours, version 1.1. Overall
survival in the PD-L1 positive (C) and intention-to-treat populations (D) at the second interim analysis. The overall survival analysis in the intention-to-treat population did not pass the prespecified
 boundary. p values reported for results other than the co-primary endpoints are provided for descriptive purposes only. HR=hazard ratio. ITT-intention to treat. NE=not estimable. PD-
L1=programmed death-ligand 1.
ensure sufficient power to test both co-primary endpoints. analysis of progression-free survival was triggered by
If progression-free survival was significant, we recycled 236 progression-free survival events (65% event-to-patient
the =0·04 to the overall survival in the ITT poulation.23,24 ratio) in the PD-L1 positive population (362 patients) at the
We defined the ITT population as all randomly assigned projected data cutoff date of Sept 29, 2017. The co-primary
patients regardless of whether they received the assigned endpoint of progression-free survival was met; therefore,
study treatment. We defined the PD-L1 positive population the  level for overall survival testing was 0·05. We
as patients in the ITT population whose PD-L1 expression planned the first interim analysis of overall survival at the
was 1% or higher on tumour-infiltrating immune cells at time of progression-free survival primary analysis. We
the time of randomisation. We assessed progression-free used an adjusted  level of 0·0009 for the first interim
survival in patients with PD-L1 positive disease at an analysis of overall survival based on an O’Brien-Fleming 
 level of 0·04, with a power of 90% based on a target spending function calculated on the number of overall
hazard ratio (HR) of 0·65 under the stratified log-rank survival events.25 We added a second interim analysis
test. We then back-calculated the total number of patients of overall survival to the protocol after the primary
based on the number of events required. The primary progression-free survival analysis to fulfil health authority
www.thelancet.com Published online May 9, 2019 http://dx.doi.org/10.1016/S0140-6736(19)30723-8 5
)%(
lavivrus
eerf-noissergorP
C D
100
90
80
70
60
50
40
30
20
10
0
0 6 12 18 24 30 36 42 0 6 12 18 24 30 36 42
Time (months) Time (months)
Number at risk
(number censored)
Atezolizumab plus 178 169 160 147 142 135 126 119 105 65 30 12 4 ·· ·· 454 429 398 372 352 333 314 294 240 155 85 33 6 ·· ··
bevacizumab group (0) (1) (1) (2) (2) (2) (2) (3) (13) (45) (76) (93)(100) (0) (2) (6) (8) (10) (10) (11) (14) (48)(118)(181)(229)(254)
Sunitinib group 184 168 154 142 138 124 116 106 86 56 32 12 1 ·· ·· 461 423 386 360 344 317 294 273 223 141 85 29 2 ·· ··
(0) (5) (7) (7) (8) (9) (9) (10) (22) (49) (72) (90)(100) (0) (12) (16) (18) (20) (22) (24) (26) (63)(135)(187)(241)(267)
)%(
lavivrus
llarevO
Median progression-free survival in the PD-L1 positive Median progression-free survival in the ITT population,
population, months (95% CI) months (95% CI)
Atezolizumab plus bevacizumab group 11·2 (8·9–15·0) Atezolizumab plus bevacizumab group 11·2 (9·6–13·3)
Sunitinib group 7·7 (6·8–9·7) Sunitinib group 8·4 (7·5–9·7)
HR 0·74 (95% CI 0·57–0·96); p=0·0217 HR 0·83 (95% CI 0·70–0·97); p=0·0219
12-month progression-free survival 12-month progression-free survival
49% (95% CI 41–56) 48% (95% CI 43–53)
12-month progression-free survival
12-month progression-free survival 41% (95% CI 36–45)
38% (95% CI 31–45)
Median overall survival in the PD-L1 positive population, Median overall survival in the ITT population, months
months (95% CI) (95% CI)
Atezolizumab plus bevacizumab group 34·0 (28·6–NE) Atezolizumab plus bevacizumab group 33·6 (29·0–NE)
Sunitinib group 32·7 (23·3–NE) Sunitinib group 34·9 (27·8–NE)
HR 0·84 (95% CI 0·62–1·15); p=0·2857 HR 0·93 (95% CI 0·76–1·14); p=0·4751
24-months overall survival 24-months overall survival
66% (95% CI 59%–73%) 63% (95% CI 58%–67%)
24-months overall survival
24-months overall survival 60% (95% CI 56%–65%)
57% (95% CI 49%–64%)
Articles
accuracy and completeness. All authors had full access to
PD-L1 positive (n=362) Intention to treat (n=915)
all the data in the study, contributed to drafts of the
Atezolizumab Sunitinib Atezolizumab plus Sunitinib manuscript, and gave final approval to publish. The
plus bevacizumab (n=184) bevacizumab (n=461)
corresponding author had final responsibility for the
(n=178) (n=454)
decision to submit for publication.
Proportion of patients 76 (43%; 35–50) 64 (35%; 28–42) 166 (37%; 32–41) 153 (33%; 29–38)
who achieved a
Results
confirmed objective
response* The study enrolled 915 patients in the ITT population
Complete response 16 (9%) 8 (4%) 24 (5%) 10 (2%) between May 20, 2015, and Oct 12, 2016, at 152 sites across
Partial response 60 (34%) 56 (30%) 142 (31%) 143 (31%) 21 countries; 454 patients were randomly assigned to
Stable disease 56 (32%) 64 (35%) 178 (39%) 178 (39%) receive atezolizumab plus bevacizumab and 461 patients
Progressive disease 34 (19%) 38 (21%) 80 (18%) 87 (19%) to receive sunitinib (figure 1). A total of 362 (40%) of
Not evaluable† 12 (7%) 18 (10%) 30 (7%) 42 (9%) 915 patients had PD-L1 positive tumours. Baseline
Duration of response, NR (12–NR) 12·9 (10–NR) 16·6 (15–NR) 14·2 (11–NR) characteristics were well balanced between study groups
months and between the PD-L1 positive and ITT populations
Ongoing responder 49 (64%) 34 (53%) 107 (64%) 90 (59%) (table 1). Overall, 142 (16%) patients had tumours with a
Data are n (%), n (%; 95% CI), or median (95% CI). Investigator-assessed according to Response Evaluation Criteria in component of sarcomatoid differentiation. At data cutoff
Solid Tumours, version 1.1. NR=not reached. PD-L1=programmed death-ligand 1. *Objective response assessed by for the primary progression-free analysis, the minimum
investigators in patients with measurable disease at baseline. †Including patients with no post-baseline tumour
survival follow-up was 12 months (median survival follow-
assessment.
up was 16 months in the PD-L1 positive population and
Table 2: Confirmed best objective response 15 months in the and ITT population).
Of 362 patients with PD-L1 positive disease, 243 (67%)
requirements. We did the second interim overall survival had disease progression or died. The study met the co-
analysis approximately 10 months after the first interim primary endpoint of investigator-assessed progression-
analysis, with an adjusted  level of 0·0076 based on an free survival, with a median progression-free survival
O’Brien-Fleming  spending function calculated on the of 11·2 months with atezolizumab plus bevacizumab
number of overall survival events. We did not update any and 7·7 months with sunitinib; stratified HR was
other study endpoints at that time. We compared 0·74 (95% CI 0·57–0·96; p=0·0217). At 12 months,
treatment groups for progression-free survival and overall progression-free survival was 49% (41–56) with atezoli-
survival using a two-sided, stratified log-rank test. We zumab plus bevacizumab versus 38% (31–45) with
used stratified Cox regression models to estimate HRs sunitinib (figure 2A; appendix). 76 (43%) of 178 patients
and 95% CIs. We assessed the proportional hazards (35–50) achieved a confirmed objective response in the
assumption of the Cox regression model and no evidence atezolizumab plus bevacizumab group, with 16 (9%)
of violation was observed. We provide p values for results achieving a complete response; 64 (35%) of 184 patients
other than the co-primary endpoints for descriptive (28–42) in the sunitinib group achieved a confirmed
purposes only. We used the Kaplan-Meier method to objective response, with eight (4%) patients achieving a
estimate survival curves and time to patient-reported complete response (table 2). At the data cutoff, 49 (64%)
deterioration in symptom interference. We estimated of 76 responses in the atezolizumab plus bevacizumab
patient-reported symptom-severity score changes from group and 34 (53%) of 64 responses in the sunitinib
baseline up to end of treatm ent and differences between group were ongoing (table 2; appendix).
groups using linear mixed-effects models. We assessed In the ITT population, 592 (65%) of 915 patients had
safety analyses, including summaries of adverse events, in disease progression or death. Progression-free survival
patients who received any amount of any component of benefit was also identified in the atezolizumab plus
study treatment. bevacizumab group (median progression-free survival
Statistical analyses were done using SAS version 9.4. was 11·2 months) versus the sunitinib group (8·4 months)
Full details of the statistical plan are included in the in the ITT population; stratified HR was 0·83 (95% CI
appendix. An independent data monitoring committee 0·70–0·97). At 12 months, 196 (48%) of 454 patients
reviewed safety data during the study on a periodic basis (43–53) in the atezolizumab plus bevacizumab group had
(approximately every 6 months). This trial is registered progression-free survival versus 166 (41%) of 461 patients
with ClinicalTrials.gov, number NCT02420821. (36–45) in the sunitinib group (figure 2B; appendix).
166 (37%) of 454 patients (32–41) in the atezolizumab
Role of the funding source plus bevacizumab group achieved a confirmed objective
F Hoffmann–La Roche Ltd and Genentech Inc sponsored response in the ITT population, with 24 (5%) achieving a
the study and collaborated with academic authors complete response; and 153 (33%) of 461 patients (29–38)
regarding study design and data collection, data analysis, in the sunitinib group achieved a confirmed objective
and data interpretation. All authors verify that this study response, with 10 (2%) achieving a complete response
was done according to the protocol and attested for data (table 2). At the data cutoff, 107 (64%) of 166 responses
6 www.thelancet.com Published online May 9, 2019 http://dx.doi.org/10.1016/S0140-6736(19)30723-8
Articles
in the atezolizumab plus bevacizumab group and
A
90 (59%) of 153 responses in the sunitinib group were
Patients (n) HR (95% CI)
ongoing (table 2; appendix).
Progression-free survival benefit was observed with Liver metastasis
atezolizumab plus bevacizumab versus sunitinib in Yes 63 0·67 (0·39–1·17)
patients across key clinical subgroups, including MSKCC No 299 0·75 (0·57–1·00)
risk groups, sarcomatoid histology, liver metastasis, and Nephrectomy
previous nephrectomy (figure 3A; appendix). Notably, the Yes 302 0·71 (0·54–0·94)
progression-free survival HR in patients with sarcomatoid No 60 0·80 (0·43–1·49)
Sarcomatoid
histology was 0·46 (95% CI 0·28–0·78) in the PD-L1
Yes 86 0·46 (0·28–0·78)
positive population and 0·56 (0·38–0·83) in the ITT
No 275 0·87 (0·64–1·17)
population. In this subgroup of the ITT population,
MSKCC risk
33 (49%) of 68 patients achieved an objective response
Favourable 64 0·62 (0·32–1·20)
with atezolizumab plus bevacizumab versus ten (14%) of
Intermediate 267 0·79 (0·59–1·06)
74 patients with sunitinib. Progression-free survival was Poor 31 0·52 (0·22–1·23)
also analysed by extent of PD-L1 status, showing a IMDC risk
gradient of increasing benefit with increasing PD-L1 Favourable 68 0·71 (0·39–1·29)
expression (figure 3B). Intermediate 232 0·81 (0·59–1·13)
Radiographic efficacy endpoints were also assessed by an Poor 62 0·65 (0·36–1·15)
IRC as a secondary endpoint. IRC-assessed progression- All patients (PD-L1 positive) 362 0·73 (0·57–0·94)
free survival resulted in a stratified HR of 0·93 (95% CI
0·2 1·0 2·0
0·72–1·21) in the PD-L1 positive population and 0·88
(0·74–1·04) in the ITT population when comparing the Favours atezolizumab Favours sunitinib
plus bevacizumab
atezolizumab plus bevacizumab group versus the sunitinib
group. Notably, in the IRC analysis, patients with PD-L1 B
negative disease (PD-L1 tumour-infiltrating immune Tumour-infiltrating immune Patients (n) HR (95% CI)
cell immunohistochemistry expression <1%) unexpectedly cell expressing PD-L1
showed an improved HR (0·84 [0·67–1·04]) compared
0 (<1%) 552 0·93 (0·75–1·15)
with patients with PD-L1 positive disease (appendix). In
1, 2, or 3 (≥1%) 363* 0·73 (0·57–0·94)
the PD-L1 positive population, 36% (64 of 178) of patients
achieved an objective response with atezolizumab plus 0 (<1%) 552 0·93 (0·75–1·15)
bevacizumab and 33% (60 of 184) with sunitinib, including 1 (1–4%) 253 0·78 (0·57–1·06)
2 (5–9%) 72 0·69 (0·38–1·22)
15% (26 of 178) who achieved a complete response
3 (≥10%) 38 0·56 (0·26–1·19)
with atezolizumab plus bevacizumab and 8% (15 of 184)
All patients 915 0·84 (0·72–0·99)
with sunitinib (appendix). Progressive disease event con-
cordance rates between investigator and IRC assessment 0·2 1·0 2·0
were high at approximately 80% and were similar between
Favours atezolizumab Favours sunitinib
the PD-L1 positive and ITT populations and between both plus bevacizumab
treatment groups.
No imbalances in progressive disease event con- Figure 3: Progression-free survival subgroup analyses
(A) Subgroup analyses of investigator-assessed progression-free survival in the PD-L1 positive population.
cordance between treatment groups were observed in the
The MSKCC prognostic risk groups are based on the presence of 0 (favourable), 1, or 2 (intermediate), or 3 or
ITT population. However, numerically more patients had more (poor) of the prognostic factors Karnofsky performance status less than 80, corrected serum calcium
disease progression according to IRC assessment than concentration higher than 10 mg/dL, lactate dehydrogenase concentration higher than 1·5 times the upper limit
of normal, haemoglobin concentration lower than the lower limit of normal, time from nephrectomy to systemic
with investigator assessment in the atezolizumab plus
therapy 12 months or less. The IMDC risk group was derived ad hoc from baseline data collected in electronic case
bevacizumab group (n=22) than in the sunitinib group
report forms. (B) Subgroup analyses of investigator-assessed progression-free survival in the intention-to-treat
(n=10) of the PD-L1 positive population. The difference population based on PD-L1 tumour-infiltrating immune cell expression status according to central laboratory
between groups was primarily caused by disease (VENTANA PD-L1 [SP142] assay). HR=hazard ratio. IMDC=International Metastatic Renal Cell Carcinoma
Database Consortium. MSKCC=Memorial Sloan Kettering Cancer Center. PD-L1=programmed death-ligand 1.
progression with appearance of new lesions (most
*One patient had a PD-L1 tumour-infiltrating immune cell immunohistochemistry expression less than
commonly in lymph nodes) in the atezolizumab plus
1% according to interactive voice and web response system and PD-L1 tumour-infiltrating immune cell
bevacizumab group, while the total number of target immunohistochemistry expression 1% or higher according to central laboratory.
lesion and non-target lesion progression events was
similar between groups (appendix). The difference For the co-primary endpoint of overall survival in the
between the IRC progressive disease event and the last ITT population, 123 (27%) of 454 patients in the
investigator assessment or death exceeded 6 months in atezolizumab plus bevacizumab group and 141 (31%) of
approximately 50% of the patients and 12 months in 461 patients in the sunitinib group had died at the data
approximately 20% of patients. Most of these patients cutoff for the first interim analysis; stratified HR was
were still on study at data cutoff. 0·81 (95% CI 0·63–1·03; p=0·0895). The results did not
www.thelancet.com Published online May 9, 2019 http://dx.doi.org/10.1016/S0140-6736(19)30723-8 7
Articles
cross the prespecified significance boundary of group and 64 (35%) of 184 patients in the sunitinib
=0·0009. In the PD-L1 positive population, 45 (25%) of group had died at data cutoff; stratified HR was 0·68
178 patients in the atezolizumab plus bevacizumab (0·46–1·00; p=0·0470). Of the 166 (36%) of 461 patients
receiving subsequent systemic cancer therapy in the
sunitinib group, approximately half received treatment
A
with a PD-L1–PD-1 inhibitor (appendix).
Atezolizumab plus bevacizumab Sunitinib
At the data cutoff for the second overall survival interim
analysis, 194 (43%) of 454 patients in the atezolizumab
plus bevacizumab group and 192 (42%) of 461 patients in
the sunitinib group had died; stratified HR was 0·93
(95% CI 0·76–1·14; p=0·4751) in the ITT population
(figure 2D). The results did not cross the prespecified
significance boundary of =0·0076, and survival follow-
up is continuing to the next planned survival analyses. In
the PD-L1 positive population, 74 (42%) of 178 patients in
the atezolizumab plus bevacizumab group and 83 (45%)
of 184 patients in the sunitinib group had died at data
cutoff; stratified HR was 0·84 (0·62–1·15; p=0·2857;
All-grade adverse All-grade adverse figure 2C). 238 (52%) of 461 patients had received
events events subsequent systemic cancer therapy, and 139 (30%)
Grade 3–4 adverse Grade 3–4 adverse
received subsequent treatment with a PD-L1–PD-1
events events
inhibitor in the sunitinib group (appendix). 103 (22%)
had received a PD-L1–PD-1 inhibitor as second-line
therapy immediately after study treatment in the
B sunitinib group versus less than 1% in the atezolizumab
100 plus bevacizumab group.
90 A total of 897 patients received atezolizumab plus
80 bevacizumab (n=451) or sunitinib (n=446); safety
70 outcomes analysed at the primary progression-free
60 survival analysis are summarised in the appendix.
50 Patients had a median treatment duration of 12·0 months
40 in the atezolizumab (IQR 4·8–16·5) plus bevacizumab
30 (4·2–15·9) group and 9·2 months (3·6–15·5) in the
20 sunitinib group. A total of 143 (32%) patients in the
10 atezolizumab plus bevacizumab group and 124 (28%)
0 patients in the sunitinib group were treated beyond
0 3 6 9 12 15 18 21 24 27 investigator-assessed, RECIST-defined progression, as
Number at risk Time (months) permitted according to the protocol. Treatment-related
(number censored) adverse events occurred in 411 (91%) patients in the
Atezolizumab plus 454 (0) 256 (104)196 (126)154 (143)128 (157) 74 (205) 35 (240) 12 (262) 3 (271) ··
bevacizumab atezolizumab plus bevacizumab group and 429 (96%) in
Sunitinib 461 (0) 178 (136)119 (153) 87 (161) 60 (176) 38 (194) 25 (206) 7 (220) 1 (224) ·· the sunitinib group. Patients given atezolizumab plus
Figure 4: Treatment-related adverse events and patient-reported outcomes
(A) Treatment-related adverse events with 20% or higher frequency in either
group and more than 5% difference between groups are shown in the tornado
plot. (B) Kaplan-Meier estimates denote time to clinically relevant deterioration
(defined as a patient’s first ≥2-point MDASI interference score increase above
baseline) of patients’ daily functioning in the intention-to-treat population.
Time to deterioration in MDASI interference scores included patient-reported
outcome data collected at study treatment visits every 3 weeks. p values
reported for results other than the co-primary endpoints are provided for
descriptive purposes only. (C) The five most severe symptoms reported by
patients based on largest numeric MDASI symptom score increase from baseline
in either group. MDASI score range, 0–10. Range across 17 symptom severity
mean scores (SD) at baseline: 0·2 (0·7) for mouth or throat sores to 2·6 (2·8) for
fatigue in the atezolizumab plus bevacizumab group versus 0·3 (0·9) for mouth
or throat sores to 2·5 (2·6) for fatigue in the sunitinib group. HR=hazard ratio.
MDASI=MD Anderson Symptom Inventory.
8 www.thelancet.com Published online May 9, 2019 http://dx.doi.org/10.1016/S0140-6736(19)30723-8
)%(
etar
eerf-noitaroireteD
Median time to symptom interference, months (95% CI)
Atezolizumab plus bevacizumab group 11·3 (8·3–17·5)
Sunitinib group 4·3 (3·1–5·6)
HR 0·56 (95% CI 0·46–0·68); p<0·0001
Rash or
skin change
Fatigue
Mouth or
throat sores
Dry mouth
Lack of
appetite
0 0·5 1·0 1·5 2·0 2·5
stneitap
yb
detroper
smotpmys
ereves
tsom
eviF
Diarrhoea
Palmar-plantar
erythrodysesthesia
Hypertension
Fatigue
Nausea
Dysgeusia
Decreased appetite
Mucosal inflammation
Stomatitis
Asthenia
Vomiting
Proteinuria
60 50 40 30 20 10 0 10 20 30 40 50 60
Proportion of patients (%)
C Mean change from baseline (95% CI)
Atezolizumab plus
bevacizumab group
Sunitinib
More severe compared with baseline
Articles
bevacizumab versus sunitinib had fewer treatment- Discussion
related grade 3–4 adverse events (182 [40%] of 451 vs This phase 3 study met its co-primary endpoint by
240 [54%] of 446) and had fewer treatment regimen showing improved progression-free survival with
discontinuations due to treatment-related adverse atezolizumab plus bevacizumab over sunitinib in
events (24 [5%] vs 37 [8%]); in the atezolizumab plus patients with metastatic renal cell carcinoma whose
bevacizumab group, additional patients had adverse disease expressed PD-L1. Clinical efficacy is supported
events leading to discontinuation of one component by a higher proportion of patients in the atezolizumab
of the study treatment (atezolizumab, nine [2%]; plus bevacizumab group achieving an objective response
bevacizumab, 23 [5%]). The median time to treatment than those in the sunitinib group, most notably the
discontinuation for atezolizumab and bevacizumab was proportion achieving a complete response. The observed
12 months. The most common grade 3–4 treatment- progression-free survival benefit of atezolizumab plus
related adverse event in the atezolizumab plus bevacizumab extended across different examined clinical
bevacizumab group was hypertension (63 [14%]); in the groups, including previous nephrectomy, sarcomatoid
sunitinib group, hypertension (75 [17%]), thrombocyto- histology, and established prognostic risk groups.
penia (24 [5%]), and palmar-plantar erythrodysaesthesia In the primary analysis, IRC-assessed progression-free
(40 [9%]) occurred most commonly (appendix). Treat- survival was generally consistent with investigator-
ment-related adverse events occurring with more than assessed progression-free survival in the ITT population.
5% difference between treatment groups are shown in However, progression-free survival results differed in
figure 4A. Five treatment-related deaths occurred in the the PD-L1 positive population. Notably, investigators and
atezolizumab plus bevacizumab group, and one death IRC reviewers were masked to patient PD-L1 status,
occurred in the sunitinib group. The most common suggesting that an evaluation bias limited to this
adverse events of special interest were rash, hypo- subgroup was unlikely. Sensitivity analyses indicated that
thyroidism, hyper thyroidism, and liver function test patients with progressive disease according to IRC, but
abnormalities, with most events being low grade not investigator, in the atezolizumab plus bevacizumab
(appendix). 74 (16%) of 451 patients given atezolizumab group were key contributors to the difference observed in
plus bevacizumab received systemic corticosteroids and the PD-L1 positive population. Among the 22 patients in
42 (9%) received high-dose systemic corticosteroids this subgroup, identification of new lesions was the
within 30 days of an adverse event of special interest primary reason that led to differing progressive disease
(high-dose systemic corticosteroid use was defined as assessments. Lymph nodes were the most common site
prednisone ≥40 mg per day or equivalent). of new lesions, a finding that might, in part, reflect the
Among all randomly assigned patients, 386 (86%) of mode of action of immunotherapy rather than clinically
451 patients in the atezolizumab plus bevacizumab relevant disease progression. Half of these patients had
group and 369 (83%) of 446 patients in the sunitinib been followed up for more than 6 months beyond IRC-
group completed the MDASI at baseline. The proportion assessed progressive disease, with stable or decreasing
of patients who completed the MDASI until cycle 7 target lesions according to both IRC and investigator, an
day 22 (week 57), when day-22 clinic visits were observation that supports continued disease control and
no longer required for patients receiving sunitinib, treatment benefit.
were similar between groups (both ≥70%). In the For the second overall survival interim analysis,
ITT population, median time to clinically relevant 386 (42%) of 915 patients had experienced an overall
deterioration of daily functioning due to treatment- survival event at data cutoff. Results did not cross the
related and disease-related symptoms was signifi- prespecified  boundary, and the study will continue
cantly longer in patients receiving atezolizumab plus until the next planned survival analyses. Differing HRs
bevacizumab (11·3 months) than in patients receiving for the two overall survival interim analyses highlight the
sunitinib (4·3 months); stratified HR was 0·56 (95% CI need for more mature survival data to establish whether
0·46 to 0·68; figure 4B). Change from baseline to end of a survival benefit will emerge.
treatment in symptom severity favoured atezolizumab Progression-free survival and response benefit was
plus bevacizumab over sunitinib for 17 symptoms: observed in the context of a favourable safety profile
lack of appetite, rash or skin change, diarrhoea, mouth with atezolizumab plus bevacizumab versus sunitinib.
or throat sores, dry mouth, nausea, fatigue, sad feelings, The safety profile was consistent with previous studies,11
vomiting, shortness of breath, distress, drowsiness, and no new or additive safety signals were identified.
disturbed sleep, pain, numbness or tingling, difficulty Atezolizumab plus bevacizumab was associated with
remembering things, and headache—listed from fewer severe treatment-related adverse events, a lower
highest difference in least-squares mean change (–1·19 regimen discontinuation rate, and low need for cortico-
[–1·46 to –0·91] for lack of appetite) to the lowest (–0·05 steroid use. Except for proteinuria, a well described
[–0·26 to 0·16] for headache). The five most severe adverse event associated with bevacizumab treatment,
symptoms reported by patients during study treatment all treatment-related adverse events were reported
are displayed in figure 4C. more commonly in the sunitinib group, including
www.thelancet.com Published online May 9, 2019 http://dx.doi.org/10.1016/S0140-6736(19)30723-8 9
Articles
gastroi ntestinal and skin adverse events often associated was enhanced in this histological subgroup, with
with quality-of-life impairment. Results of the prespecified 86 (61%) of 142 patients expressing PD-L1. However,
patient-reported outcomes analyses further supported patients in the atezolizumab plus bevacizumab group
this finding. A meaningful interference of symptoms showed improved progression-free survival and a higher
with patients’ daily functioning occurred significantly proportion achieved a response compared with those in
later in the atezolizumab plus bevacizumab group than the sunitinib group, with and without PD-L1 expression,
the sunitinib group, with a 7-month median delay. The supporting an independent predictive value of histology.
median time to symptom interference with daily living In summary, this trial showed a progression-free survival
coincided with median progression-free survival with advantage with the combination of atezolizumab plus
atezolizumab plus bevacizumab, whereas patients in the bevacizumab over sunitinib in patients with previously
sunitinib group had functional impairment significantly untreated metastatic renal cell carcinoma, with a favourable
earlier than radiographic progression. In addition, safety profile. Overall survival did not cross the significance
patients in the atezolizumab plus bevacizumab group boundary, and longer-term follow-up is necessary to
reported milder treatment-related and disease-related establish whether a survival benefit will emerge.
symptoms than those in the sunitinib group.
Contributors
Results reported here corroborate the clinical activity of BIR, TP, MBA, BE, DFM, CSu, and RJM designed the study. All authors
PD-L1–PD-1 checkpoint inhibitor-based combinations in contributed to data collection, data analysis, and data interpretation.
All authors contributed to the writing of the manuscript, approved the
previously untreated metastatic renal cell carcinoma, as
final version, and agree to be accountable for all aspects of the report.
published for the combinations of nivolumab plus
Declaration of interests
ipilimumab and avelumab plus axitinib.8,26 Although
BIR has received grants and honoraria from Roche–Genentech and Pfizer
cross-trial comparisons are limited by study design and during the conduct of the study and has received grants to his institution
patient populations, results from these investigations and honoraria for consulting roles from Merck, Peloton, Aveo,
add to the growing evidence of PD-L1 expression on Bristol-Myers Squibb, grants to his institution from AstraZeneca,
honoraria for consulting roles from Novartis, Synthorx, Compugen,
either tumour cells or tumour-infiltrating immune cells
Corvus, Exelixis, and holds stock in PTC therapeutics, all outside of the
being associated with enriched clinical benefit with submitted work. TP has received research funding from AstraZeneca and
checkpoint inhibition and negative prognostic value in Roche, and honoraria from AstraZeneca, Roche, Bristol-Myers Squibb,
metastatic renal cell carcinoma.6,7,27,28 Pfizer, Novartis, Exelixis, and Merck Sharp & Dohme outside of the
submitted work. MBA has received grants from Roche–Genentech during
PD-L1 expression on tumour-infiltrating immune
the conduct of the study and honoraria for consulting roles outside of the
cells was previously reported to be strongly associated submitted work from Roche–Genentech, Bristol-Myers Squibb, Merck,
with expression of T-effector and interferon gamma Novartis, Pfizer, Exelixis, and Esai. BE has received grants and honoraria
gene signatures, a hallmark of pre-existing antitumoural from Bristol-Myers Squibb, Novartis, Ipsen, and EUSA outside of the
submitted work. DFM has received grants from Bristol-Myers Squibb and
immunity.11 A consistent pattern of improved progression-
Prometheus and honoraria for consulting roles from Bristol-Myers
free survival with increasing levels of PD-L1 tumour- Squibb, Pfizer, Merck, Novartis, Eisai, Exelixis, Array BioPharm, and
infiltrating immune cell expression was observed in Genentech BioOncology outside of the submitted work. SB has received
IMmotion151. This finding underscores the relevance honoraria and travel support for advisory roles from Novartis, Astellas,
Janssen, Pfizer, Bristol-Myers Squibb, Roche, and Ipsen, honoraria from
of pre-existing immunity in differentiating the clinical
Merck Sharp & Dohme, and travel support from Exelixis outside the
activity of atezolizumab plus bevacizumab versus submitted work. WMS has received honoraria from Roche and Pfizer for
sunitinib and substantiates PD-L1 immunohistochemistry advisory roles outside of the submitted work. FD has received grants from
as a supporting tool for treatment selection in patients Pfizer, Novartis, and Ipsen outside of the submitted work. JLL has
received study medication for investigator-sponsored trials from Pfizer
with metastatic renal cell carcinoma.
and Samyang and honoraria from Bristol-Myers Squibb outside of the
The combination of nivolumab plus ipilimumab submitted work. RH has received honoraria from Novartis, Ipsen, EUSA,
showed improved overall survival and objective response and Pfizer, honoraria and travel support from Bristol-Myers Squibb, and
in patients with intermediate and poor prognostic risk patent royalties outside of the submitted work. AR has received honoraria
and travel support for advisory roles from Pfizer, Novartis, Roche, and
as assessed by the International Metastatic Renal Cell
Bristol-Myers Squibb during the conduct of the study. BA has received
Carcinoma Database Consortium score, whereas patients grants from Roche during the conduct of the study and grants, honoraria,
with favourable risk showed numerically superior and travel support from Roche, AstraZeneca, Janssen, Pfizer, Merck, and
Sanofi outside of the submitted work. MS has received institutional grants
results for overall survival, progression-free survival, and
from Roche–Genentech during the conduct of the study, grants and
objective response with sunitinib.8 The results reported
honoraria from Pfizer, Novartis, and Ipsen, and honoraria from EUSA
here, with combined VEGF and checkpoint inhibition, Pharma and Bristol-Myers Squibb outside of the submitted work. MU has
corroborated by phase 3 results for avelumab plus received honoraria for advisory roles from Chugai Pharmaceuticals
outside of the submitted work. UDG has received honoraria from
axitinib,26 suggest a progression-free survival benefit
Bristol-Myers Squibb, Pfizer, Novartis, Ipsen, Astellas, Bayer, Sanofi,
across prognostic risk groups, including in patients with
and Janssen outside of the submitted work. CP has received honoraria
favourable prognostic risk. from Bristol-Myers Squibb, Pfizer, Novartis, Ipsen, EUSA, Eisai,
Additionally, this trial showed substantial efficacy in and Janssen outside of the submitted work. BMeli has received honoraria
and travel support for advisory roles from Roche, Novartis, Bristol-Myers
patients with a sarcomatoid histology component, a
Squibb, Merck Sharp & Dohme, and Merck Serono, and honoraria for
patient group with a particularly poor prognosis and advisory roles from Pfizer, Astellas, AstraZeneca, Bayer, Pierre Fabre,
limited response to VEGF inhibition.29 PD-L1 expression and Janssen outside of the submitted work. HG has received grants and
10 www.thelancet.com Published online May 9, 2019 http://dx.doi.org/10.1016/S0140-6736(19)30723-8
Articles
honoraria from Pfizer, and honoraria from Roche and Bristol-Myers 9 Motzer RJ, McCann L, Deen K. Pazopanib versus sunitinib in renal
Squibb outside of the submitted work. JB has received grants and cancer. N Engl J Med 2013; 369: 1970.
honoraria from Roche, Bristol-Myers Squibb, Pfizer, Novartis, Eisai, 10 Patel S, Keohan ML, Saif MW, et al. Phase 2 study of intravenous
and Merck Sharp & Dohme and honoraria from Ipsen, EUSA Pharma, TZT-1027 in patients with advanced or metastatic soft-tissue sarcomas
and Nektar outside of the submitted work. TKC has received grants and with prior exposure to anthracycline-based chemotherapy. Cancer
honoraria from Bristol-Myers Squibb and honoraria from Roche, Pfizer, 2006; 107: 2881–87.
Merck, Eisai, and Novartis during the conduct of the study. TK is an 11 McDermott DF, Huseni MA, Atkins MB, et al. Clinical activity and
employee of F Hoffmann–La Roche, Ltd. AT is an employee of Roche molecular correlates of response to atezolizumab alone or in
combination with bevacizumab versus sunitinib in renal cell
Products Ltd. SL, EP-L, GF, MH, CSc, and MCG are employees of
carcinoma. Nat Med 2018; 24: 749–57.
Genentech Inc. RJM has received honoraria for advisory roles from
12 Motzer RJ, Rini BI, McDermott DF, et al. Nivolumab for metastatic
Roche–Genentech, Pfizer, Novartis, Exelixis, Eisai, and Merck,
renal cell carcinoma: results of a randomized phase 2 trial.
and institutional support from Bristol-Myers Squibb, Roche–Genentech,
J Clin Oncol 2015; 33: 1430–37.
Pfizer, Novartis, Exelixis, and Eisai outside of the submitted work.
13 Escudier B, Cosaert J, Jethwa S. Targeted therapies in the
CSu, FP, and BMell have nothing to disclose.
management of renal cell carcinoma: role of bevacizumab.
Data sharing Biologics 2008; 2: 517–30.
Qualified researchers can request access to individual patient-level 14 Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and
data through the clinical study data request platform development of bevacizumab, an anti-VEGF antibody for treating
(www.clinicalstudydatarequest.com). Further details on Roche’s criteria cancer. Nat Rev Drug Discov 2004; 3: 391–400.
for eligible studies are available here: https://clinicalstudydatarequest. 15 Gabrilovich DI, Chen HL, Girgis KR, et al. Production of vascular
com/Study-Sponsors/Study-Sponsors-Roche.aspx. For further details endothelial growth factor by human tumors inhibits the functional
on Roche’s Global Policy on the Sharing of Clinical Information and maturation of dendritic cells. Nat Med 1996; 2: 1096–103.
how to request access to related clinical study documents, see here 16 Oyama T, Ran S, Ishida T, et al. Vascular endothelial growth factor
http://www.roche.com/research_and_development/who_we_are_how_ affects dendritic cell maturation through the inhibition of nuclear
factor-kappa B activation in hemopoietic progenitor cells. J Immunol
we_work/clinical_trials/our_commitment_to_data_sharing.htm.
1998; 160: 1224–32.
Acknowledgments 17 Hodi FS, Lawrence D, Lezcano C, et al. Bevacizumab plus
This study was sponsored by F Hoffmann–La Roche Ltd and Genentech ipilimumab in patients with metastatic melanoma.
Inc, a member of the Roche Group. We thank the patients participating Cancer Immunol Res 2014; 2: 632–42.
in this trial and the clinical study site investigators (appendix). We also 18 Wallin JJ, Bendell JC, Funke R, et al. Atezolizumab in combination
thank Gregg D Fine, Daniel S Chen, Priti S Hegde, and Cathi Ahearn for with bevacizumab enhances antigen-specific T-cell migration in
their contributions to the study design; Daniel S Chen, Priti S Hegde, metastatic renal cell carcinoma. Nat Commun 2016; 7: 12624.
Mika Derynck, Brian Pelkowski, and Susheela Carroll for their input in 19 Hegde PS, Wallin JJ, Mancao C. Predictive markers of anti-VEGF and
data interpretation; Caroleen Quach for her involvement with emerging role of angiogenesis inhibitors as immunotherapeutics.
patient-reported outcome assessments; and Flavia DiNucci and Xiaohui Semin Cancer Biol 2017; 52: 117–24.
Wen for their contributions to safety analyses. Patients treated at 20 Chen DS, Mellman I. Oncology meets immunology:
Memorial Sloan Kettering Cancer Center were supported in part by the cancer-immunity cycle. Immunity 2013; 39: 1–10.
Memorial Sloan Kettering Cancer Center Support Grant/Core Grant 21 Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J.
(P30 CA008748). Support for third-party writing assistance for this Survival and prognostic stratification of 670 patients with advanced
renal cell carcinoma. J Clin Oncol 1999; 17: 2530–40.
manuscript, furnished by Paige S Davies of Health Interactions, was
provided by F Hoffmann–La Roche Ltd. 22 Cleeland C. The MD Anderson Symptom Inventory User Guide.
Houston, TX, USA: The University of Texas MD Anderson Cancer
References Center, 2009. https://www.mdanderson.org/documents/
1 Escudier B, Porta C, Schmidinger M, et al. Renal cell carcinoma: Departments-and-Divisions/Symptom-Research/MDASI_
ESMO clinical practice guidelines for diagnosis, treatment and userguide.pdf (accessed March 28, 2019).
follow-up. Ann Oncol 2016; 27: v58–68. 23 Bretz F, Maurer W, Brannath W, Posch M. A graphical approach to
2 National Comprehensive Cancer Network Clinical Practice sequentially rejective multiple test procedures. Stat Med 2009;
Guidelines in Oncology. Kidney cancer, version 2. 2019. 28: 586–604.
https://www.nccn.org/professionals/physician_gls/PDF/kidney.pdf 24 Burman CF, Sonesson C, Guilbaud O. A recycling framework for
(accessed March 28, 2019). the construction of Bonferroni-based multiple tests. Stat Med 2009;
3 Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell 28: 739–61.
carcinoma. N Engl J Med 2017; 376: 354–66. 25 Lan K, DeMets D. Discrete sequential boundaries for clinical trials.
4 Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell Biometrika 1983; 70: 659–63.
carcinoma. Lancet Oncol 2009; 10: 992–1000. 26 Motzer RJ, Penkov K, Haanen JBAG, et al. JAVELIN Renal 101:
5 Ljungberg B, Bensalah K, Canfield S, et al. EAU guidelines on renal a randomized, phase 3 study of avelumab + axitinib vs sunitinib as
cell carcinoma: 2014 update. Eur Urol 2015; 67: 913 –24. first-line treatment of advanced renal cell carcinoma (aRCC).
6 Choueiri TK, Figueroa DJ, Fay AP, et al. Correlation of PD-L1 tumor Ann Oncol 2018; 29: LBA6_PR (abstr).
expression and treatment outcomes in patients with renal cell 27 Thompson RH, Kuntz SM, Leibovich BC, et al. Tumor B7-H1 is
carcinoma receiving sunitinib or pazopanib: results from COMPARZ, associated with poor prognosis in renal cell carcinoma patients with
a randomized controlled trial. Clin Cancer Res 2015; 21: 1071–77. long-term follow-up. Cancer Res 2006; 66: 3381–85.
7 Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus 28 Tykodi SS. PD-1 as an emerging therapeutic target in renal cell
everolimus in advanced renal-cell carcinoma. N Engl J Med 2015; carcinoma: current evidence. Onco Targets Ther 2014; 7: 1349–59.
373: 1803–13. 29 Mouallem NE, Smith SC, Paul AK. Sarcomatoid renal cell
8 Motzer RJ, Tannir NM, McDermott DF, et al. Nivolumab plus carcinoma: biology and treatment advances. Urol Oncol 2018;
ipilimumab versus sunitinib in advanced renal-cell carcinoma. 36: 265–71.
N Engl J Med 2018; 378: 1277–90.
www.thelancet.com Published online May 9, 2019 http://dx.doi.org/10.1016/S0140-6736(19)30723-8 11
